Pharma dealmaking for drugs invented in China is putting pressure on U.S. biotechs to compete harder, according to investors ...

Roche's core research spans five large areas. Boris Zaïtra, who now leads corporate business development, is confident his ...

The clearance broadens use of Omvoh, which is part of a slate of new medicines Lilly is counting on to build on its success ...

AbbVie's CEO hinted his company may be less willing to invest in psychiatry after a costly setback, while Lilly explained ...

The pharma began submitting its TAR-200 bladder cancer treatment to the FDA. Elsewhere, Sarepta and Madrigal reported strong ...

While Biogen has made an opportunistic bid for partner Sage, its top executive seemed to play down the urgency for his ...

The review, which was spurred by controversy over the FDA's Aduhelm approval, recommends two main changes in agency ...

Faro Health Inc., the leading AI-powered platform for data-driven clinical protocol design, today announced it has partnered with Recursion (NASDAQ: RXRX) to accelerate and optimize clinical protocol ...

NULISA employs a sequential immunocomplex capture and release technique to improve the sensitivity of traditional proximity ...

Regenxbio, a prolific developer of gene therapy technology, will hand Japan’s Nippon Shinyaku certain rights to two ...

The company said it overestimated demand of its obesity and diabetes drugs in the fourth quarter, but projected a further ...

Agency commissioners voted unanimously on Tuesday to publish the report, which makes a similar attack on the drug middlemen ...